ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Relief for IBS, Colitis, Crohn’s And More

B Vitamins May Protect Against Damaging Effects of Air Pollution, and Improve Cognition and Psychiat...

Restless Leg Syndrome (RLS) - are you running a marathon each night?

Can Magnesium Relieve Your Tinnitus?

Resveratrol Proven to Slow Brain Aging

Cassia Bark Oil: Why It's Valuable in Traditional Chinese Medicine

Fruits and vegetables' latest superpower? Lowering blood pressure

Neroli Oil: The Pleasantly Fragrant Citrus Oil

Prenatal vitamin D could help prevent autism in children

Magnesium Protects Against Stroke, Heart Disease and Diabetes

 
Print Page
Email Article

Results of Parkinson's study may change treatment

  [ 89 votes ]   [ Discuss This Article ]
www.ProHealth.com • August 8, 2000


Requip (ropinirole hydrochloride) successfully managed Parkinson's disease symptoms for up to five years with a low risk of developing dyskinesia, according to a study published in The New England Journal of Medicine. Dyskinesias are severe, uncontrollable, jerky body movements that plague many Parkinson's disease patients and in many cases are associated with L-dopa (l-dopa) therapy.

L-dopa has been the "gold standard" of treatment in Parkinson's disease for the past 35 years; it is used in approximately 75 percent of patients. Unfortunately, over time Parkinson's disease progresses and physicians need to increase the dosage and frequency of l-dopa to relieve Parkinson's symptoms.

Increasing the dosage of l-dopa can cause many patients to experience l-dopa-induced side effects such as dyskinesias, which can have a negative impact on a patient's ability to function. This study confirms that Requip, alone or in combination with low dose l-dopa, is effective in managing early Parkinson's disease (Hoehn & Yahr disease stages I-III).

"The impact of this study is that it will help guide physicians to chose among a number of Parkinson's disease treatments for early management in order to minimize the long-term side effects of treatment. And it indicates that if you use Requip first, you are less likely to get dyskinesias over the course of five years," said lead study author Olivier Rascol, M.D., Ph.D. of the Centre Hospitalier Universitaire Toulouse, France. "I think these results will impact physicians' treatment strategy to help improve the daily lives of patients coping with Parkinson's disease."

Requip is generally well tolerated. The most commonly reported side effects are nausea, somnolence, dizziness, headache and dyskinesia. Patients are advised to talk to their doctor about whether they have the potential to develop the sedating effects associated with Requip, which include somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Fainting or low blood pressure may occur during initial treatment or with an increase in dose. Hallucinations may occur at anytime during treatment. Requip may potentiate the side effects of L-dopa.

"The data confirm Requip's efficacy in the early stages of the disease with a low risk of developing dyskinesia and provide strong evidence in support of starting early Parkinson's disease patients on a dopamine agonist, such as Requip," said Ray Watts, M.D., Director of the Movement Disorders Program at Emory University School of Medicine. "A study is currently underway to determine if early treatment with Requip can have an effect on dopamine cell loss, which may be helpful in furthering our understanding of the progression of Parkinson's disease. Together, these studies may provide neurologists with a deeper understanding of how to optimally treat this condition."

Requip is a second-generation dopamine agonist indicated for the treatment of the signs and symptoms of both early and advanced stages of Parkinson's disease and was approved by the U.S. Food and Drug Administration (FDA) in September 1997.

A Progressive Neurodegenerative Disorder Parkinson's disease, which affects between 500,000 and one million Americans, is a chronic and progressive disorder that results from the death of nerve cells in a critical area of the brain called the substantia nigra. These nerve cells normally produce dopamine, a chemical messenger that plays an important role in motor movement control by transmitting signals between different areas of the brain. Increasing the dosage of l-dopa can cause many patients to experience l-dopa-induced side effects such as dyskinesias, which can have a negative impact on a patient's ability to function. Dopamine depletion results in a patient's impaired ability to control motor movements.

"Parkinson's disease affects nearly one million Americans, including Michael J. Fox, Janet Reno and Muhammad Ali," said Abraham Lieberman, M.D., Clinical Director for the National Parkinson Foundation. "If we can better treat the condition in the early stages, patients may be able to live more active lives. While searching for a cure to this disease, our hope is to better manage patients who are living with it now."



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Ultra EPA  - Fish Oil Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

When a Negative is Positive - Goodnighties Recovery Sleepwear When a Negative is Positive - Goodnighties Recovery Sleepwear
Safely Burn Away Body Fat Safely Burn Away Body Fat
"It's Not Easy Being Green" - But It Is Healthy
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Herbal Rescue for High Blood Sugar Herbal Rescue for High Blood Sugar

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map